Every Form 4 that Cytokinetics Inc. (CYTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYTK filings page.
Cytokinetics (CYTK) reported a Form 4 for a director. On 10/27/2025, the insider exercised 4,375 stock options at $10 and sold 4,375 common shares at $58.68 the same day. After these transactions, the director directly owned 32,444 shares.
The option exercised was a non-qualified stock option with a $10 exercise price, first exercisable on 02/04/2016 and expiring 01/04/2026; it is now fully exercised.
Cytokinetics (CYTK) disclosed a Form 4 for its EVP of Research & Development reporting insider transactions on 10/21/2025. The officer exercised 2,105 non-derivative shares via an option at $10.60 per share (code M) and sold 2,105 shares at $58.22 (code S) on the same date. Following these transactions, the reporting person directly holds 140,610 shares of common stock. A non-qualified stock option with an exercise price of $10.60, initially exercisable on 03/28/2017 and expiring on 02/28/2027, shows 1,000 derivative securities beneficially owned after the reported activity.
Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4. A company director acquired 99 shares of common stock on 10/15/2025 at a price of $62.8 per share. The filing notes the transaction code A (1), with the footnote stating, “Director equity in lieu of cash retainer program,” indicating this was a stock grant in place of cash fees.
Following the transaction, the director now beneficially owns 32,444 shares, held directly. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported an insider transaction. President & CEO sold 5,000 shares of common stock on 10/16/2025 at $60.03 per share. Following the sale, the reporting person beneficially owns 363,108 shares directly.
Additional indirect holdings are disclosed as 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.